Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2023-05-08
2024-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon
NCT01858428
Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study
NCT00673985
Drug Eluting Temporary Spur Stent System vs Percutaneous Balloon Angioplasty for the Treatment of Critical Limb Ischemia
NCT06122974
Phitys I™ Percutaneous Left Ventricular Assist System Study
NCT06357026
A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease
NCT05335161
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Magenta Elevate™ Pump is a catheter-mounted, self-expanding and retrievable pump, designed to unload the left ventricle by actively transporting blood from the left ventricle into the ascending aorta.
The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HR-PCI patients
Patients undergoing non-emergent, high-risk percutaneous coronary interventions
The Elevate™ System
The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The Elevate™ System
The Magenta Elevate™ is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients, with severe coronary artery disease.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ejection fraction of ≤ 50% and at least one of the following:
1. Intervention on an unprotected left main coronary artery
2. Intervention on a last patent coronary conduit
3. Three-vessel disease (in case of left coronary artery dominance, the combination of a left anterior descending artery (LAD) lesion and a proximal left circumflex artery (LCX) lesion qualifies as three-vessel disease).
3. A heart team that includes a cardiac surgeon has determined that high-risk PCI is the appropriate therapeutic option.
4. Subject signed informed consent.
Exclusion Criteria
2. Cardiogenic shock (systolic blood pressure \< 90 mmHg with evidence of end organ hypoperfusion, such as cool extremities or urine \< 30 mL/hour); acutely decompensated pre-existing chronic heart failure; any use of inotropic or vasopressor in the previous 48 hours; or any use of mechanical circulatory support or an extracorporeal membrane oxygenation device within 14 days.
3. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis
4. Evidence of left ventricular thrombus.
5. Previous aortic valve replacement or repair or a heart-constrictive device.
6. Aortic stenosis
7. Aortic regurgitation (≥ 2+ on a 4-grade scale by Transthoracic Echocardiography).
8. Aortic pathology, such as aortic aneurysms, dissection, extreme tortuosity, calcifications, or prior aortic surgery, that could pose undue additional risk to the placement of a pLVAD device.
9. Left ventricle rupture.
10. Cardiac tamponade.
11. Subject is scheduled for a staged PCI within 90 days of the index procedure
12. Subject has any condition or scheduled surgery that will require discontinuation of the antiplatelet and/or anticoagulant therapy within 90 days of the index procedure.
13. Chronic renal dysfunction (eGFR \<30 mL/min/1.73 m²) and patients requiring renal replacement therapy with dialysis.
14. Known or suspected coagulopathy or abnormal coagulation parameters (defined as platelet count ≤ 100,000 or spontaneous INR ≥ 1.5 or known fibrinogen ≤ 1.5 g/L).
15. Infection of the proposed procedural access site or suspected systemic active infection, including any fever.
16. Active COVID-19 infection.
17. Stroke or transient ischemic attack within 6 months of enrollment.
18. Subject participation in another investigational drug or device trial (with the exception of post-market registries and observational studies, subject to Sponsor review and approval).
19. Female subjects who are pregnant or breast-feeding.
20. Any non-cardiac condition with a life expectancy \<24 months
21. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to provide written informed consent and/or to comply with study procedures.
22. Subject belongs to a vulnerable population defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of providing informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
18 Years
84 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Magenta Medical Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zohar Bronshtine
Role: STUDY_DIRECTOR
Magenta Medical Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai Hospital
New York, New York, United States
New York-Presbyterian Hospital/Columbia University Irving Medical Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DRD00417
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.